Description
Neuromexol Pharmacodynamics
Ethylmethylhydroxypyridine succinate is an inhibitor of free radical processes, a membrane protector, which has antihypoxic, stress-protective, nootropic, anticonvulsant and anxiolytic effects. The drug increases the body’s resistance to the effects of various damaging factors (shock, hypoxia and ischemia, disorders of cerebral circulation, intoxication with alcohol and antipsychotic drugs (neuroleptics)).
The mechanism of action of the drug is due to its antioxidant, antihypoxant and membrane-protective effects. It inhibits lipid peroxidation, increases superoxide dismutase activity, increases lipid-protein ratio, reduces membrane viscosity and increases membrane fluidity. Ethylmethylhydroxypyridine succinate modulates the activity of membrane-bound enzymes (calcium independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which increases their binding ability to ligands, helps maintain the structural and functional organization of biomembranes, transport neurotransmitters and improve synaptic transmission. Ethylmethylhydroxypyridine succinate increases the content of dopamine in the brain. Causes enhancement of compensatory activation of aerobic glycolysis and reduction of the degree of inhibition of oxidative processes in the Krebs cycle under hypoxia with an increase in ATP and creatine phosphate, activation of energy-synthesizing functions of mitochondria, stabilization of cell membranes.
The drug improves metabolism and blood supply to the brain, improves microcirculation and blood rheological properties, reduces platelet aggregation. It stabilizes membrane structures of blood cells (erythrocytes and platelets) during hemolysis. It has a hypolipidemic effect, reduces the content of total cholesterol and low-density lipoproteins.
Anti-stressor effect is manifested in normalization of post-stress behavior, somatovegetative disorders, restoration of sleep-wake cycles, disturbed learning and memory processes, reduction of dystrophic and morphological changes in various structures of the brain.
Ethylmethylhydroxypyridine succinate has a pronounced antitoxic effect in withdrawal syndrome. It eliminates neurological and neurotoxic manifestations of acute alcohol intoxication, restores behavioral disorders, autonomic functions, and is also able to relieve cognitive disorders caused by prolonged ethanol intake and its withdrawal. Under the influence of the drug the effect of tranquilizing, neuroleptic, antidepressant, sleeping pills and anticonvulsants increases, which allows reducing their doses and side effects. Ethylmethylhydroxypyridine succinate improves functional state of ischemic myocardium. In conditions of coronary insufficiency it increases collateral blood supply of ischemic myocardium, helps to preserve the integrity of cardiomyocytes and maintain their functional activity. Effectively restores myocardial contractility in reversible cardiac dysfunction.
Indications
-sequences of acute cerebral circulatory disorders, including after transient ischemic attacks, in the phase of subcompensation as a preventive course;
-light craniocerebral trauma, consequences of craniocerebral injuries;
Encephalopathies of different genesis (dyscirculatory, dysmetabolic, post-traumatic, mixed);
-vegetative dystonia syndrome;
-Mild cognitive disorders of atherosclerotic genesis;
-anxiety disorders in neurotic and neurosis-like conditions;
-Coronary heart disease as part of complex therapy;
-withdrawal syndrome in alcoholism with a predominance of neurosis and vegetative vascular disorders, postabstinence disorders;
-states after acute intoxication with antipsychotic agents;
-Asthenic conditions, as well as for the prevention of the development of somatic diseases under the influence of extreme factors and stress;
-Exposure to extreme (stressor) factors.
Contraindications
-acute hepatic and/or renal failure;
-High individual sensitivity to the drug;
Because of the insufficient study of the drug – childhood, pregnancy, breast-feeding.
Administration during pregnancy and breast-feeding.
The drug is contraindicated during pregnancy and breast-feeding because of the lack of data on safety and efficacy in these periods.
Directions for use and dosages
- Orally, 125-250 mg 3 times a day, the maximum daily dose – 750 mg (6 tablets).
- Duration of treatment – 2-6 weeks; for relief of alcohol withdrawal – 5-7 days. Treatment is discontinued gradually, reducing the dose over 2-3 days.
- The initial dose is 125-250 mg (1-2 tablets) 1-2 times a day with a gradual increase to obtain therapeutic effect; maximum daily dose is 750 mg (6 tablets).
- The duration of therapy in patients with coronary heart disease is at least 1.5-2 months.
- Repeated courses (as recommended by the physician) are desirable during the spring and autumn periods.
